US · Healthcare · Medical Devices
EPS came in at 0.86 against a street estimate of 0.83 — a beat of 3.6%.
Analysts rate Boston Scientific Corp a strong buy (31 buy, 3 hold, 0 sell out of 34) with an average price target of $62.00.
CAUTIOUS Q2 beat on 7% organic growth, but full-year guidance cut due to WATCHMAN market collapse and EP share losses. Company restructuring for $500M savings by 2029, expects recovery in 2028 via new product launches. Q2 2026 International strength (EMEA +4%, APAC +11%) partially offset by U.S. pressure in EP and WATCHMAN. Analysts pressed on guidance conservatism, WATCHMAN reversal strategy, EP recovery timing. Management acknowledged undercalls in share losses and market slowdowns, committed to execution despite 2027 headwinds, emphasized 2028 as inflection point via new launches and cost savings. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.10% |
| Vanguard Capital Management, LLC | 6.65% |
| FMR Inc | 5.12% |
| State Street Corp | 4.69% |
| PRIMECAP Management Company | 3.49% |
| JPMorgan Chase & Co | 2.30% |
| Geode Capital Management, LLC | 2.30% |
| Vanguard Portfolio Management, LLC | 2.06% |
| Document | Date |
|---|---|
| Current report · Q3 2026 BOSTON SCIENTIFIC CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Cybersecurity incident detected August 25, 2026; disclosed September 7, 2026 • C | 2026-09-08 |
| Company announcement · Q3 2026 BOSTON SCIENTIFIC CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Cybersecurity incident identified on August 25, 2026 • Global disruption to compa | 2026-08-26 |
| Quarterly report · Q2 2026 BOSTON SCIENTIFIC CORPORATION - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 net sales: $5,442 million (up 7.5% vs Q2 2025: $5,061 million) • H1 | 2026-08-03 |
| Results announced · Q3 2026 BOSTON SCIENTIFIC Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 net sales: $5.442 billion, up 7.5% reported / 7.0% operational and organic vs. | 2026-07-29 |
| Current report · Q3 2026 BOSTON SCIENTIFIC CORPORATION - FORM 8-K SUMMARY July 21, 2026 --- HEADLINE NUMBERS • Total restructuring charges: $700 million to $800 million (pr | 2026-07-27 |
| Quarterly report · Q1 2026 BOSTON SCIENTIFIC CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net sales Q1 2026: $5,203 million vs. $4,663 million in Q1 2025 (11.6% incre | 2026-05-01 |
| Proxy statement · Q1 2026 BOSTON SCIENTIFIC CORPORATION (BSX) - 2026 PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 10 director nominees (an | 2026-03-18 |
| Annual report FY2025 BOSTON SCIENTIFIC CORPORATION — FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Market Capitalization: $158.7 billion | 2026-02-17 |
Readable in the app.
| Announcement | Date |
|---|---|
| Cybersecurity incident likely to cause material impact on 2026 guidance Boston Scientific Corporation suffered a significant cybersecurity incident on August 25, 2026, that caused a global operational disruption. Unauthorized activity on the company's systems re | 2026-09-08 |
| Investment agreement to acquire stake in MiRus LLC with call option for full acquisition Boston Scientific announced a major strategic investment in MiRus LLC, a private company developing a novel transcatheter aortic valve replacement (TAVR) system. The deal structure includes: | 2026-05-18 |
| Accelerated share repurchase program of $2 billion announced Boston Scientific announced a $2 billion accelerated share repurchase (ASR) program with JPMorgan Chase on May 18, 2026. The company will immediately receive approximately 30.4 million share | 2026-05-18 |
| Entered into Agreement and Plan of Merger with another company Boston Scientific announced on January 14, 2026, that it will acquire Penumbra, Inc., a medical device company, through a merger. Under the deal, Penumbra shareholders can choose to receive | 2026-01-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Boston Scientific Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.